The prospect of using neural cell replacement for the treatment of severe enteric neuropathies has seen significant progress in the last decade. The ability to harvest and 
treatments are unsatisfactory and limited to surgical interventions, which are associated with high levels of morbidity and mortality. 1 Alternative therapeutic strategies are required for these conditions. 8 The ENS is formed during embryogenesis by migratory neural crest cells arising in the vagal and sacral regions of the neural tube (reviewed in Ref. 9 ). Enteric neural crest cells (ENCC), which give rise to enteric neurons, glia, and stem cells, can be isolated from both embryonic and postnatal murine intestine. 10, 11 Furthermore, upon transplantation, they are able to colonize both ganglionic and aganglionic murine bowel in vivo, forming neural networks that display functional integration with the host neuromusculature. 12, 13 The potential to develop a clinically applicable cell replacement therapy for enteric neuropathies has been validated by the isolation of ENCC from fetal and postnatal human gut 8, [14] [15] [16] To date, human gut-derived
ENCCs have been transplanted within in vitro models of aganglionosis,
showing physical integration and differentiation. 14, 15, 17 However, their
functional integration remains to be demonstrated within a postnatal in vivo model. Here, we report the efficient isolation of ENCC from human fetal gut and successful engraftment and functional integration following in vivo transplantation into immunodeficient murine gut. 14 They generated primary neurospheres after approximately 1 week, and these were transplanted within 15-30 days.
| MATERIALS AND METHODS

| Animals
| Lentiviral labeling of human ENCC
Lentiviral constructs expressing enhanced green fluorescent protein (EGFP) 20 and GCaMP (Addgene plasmid 42168:pJMK019, Adam
Cohen; Addgene, Cambridge, MA, USA) were used to label cells with high levels of GFP or a calcium-sensitive GFP construct, respectively.
Isolation of lentiviral particles and subsequent transduction of cells was conducted according to a protocol described previously.
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| Transplantation of ENCC into gut in vivo
Enteric neural crest cells were transplanted into the distal colon of
− knockout mice via laparotomy (described previously Ref. 13 ) at weaning (postnatal day 21; n = 15).
Mice were maintained for 4 weeks posttransplantation before they were killed and analyzed.
| Immunohistochemistry
Transplanted bowel was fixed and analyzed using immunohistochemistry as described previously. 13 The primary antibodies used were mouse TuJ1 (1:1000; Biolegend, London, UK) and rabbit anti-cow S100 (1:500; Dako, Ely, Cambridgeshire, UK), and secondary antibodies were anti-mouse and anti-rabbit Alexafluor 568 (1:500; Invitrogen, Carlsbad, CA, USA).
Images were acquired on a Zeiss LSM 710 confocal microscope (Zeiss, Cambridge, UK) and processed using ImageJ 21 and Adobe Photoshop CS3 software (Adobe, San Jose, CA, USA).
| Calcium imaging of transplanted ENCC
Colonic gut samples were prepared as described previously. 13 The endogenous ENS was stimulated via an electrode placed approximately 200 μm from the transplanted cells. Changes in the fluorescence intensity of GCaMP elicited by calcium transients within transplanted cells were then imaged and processed as described previously. • Upon transplantation, fetal human-derived ENCCs display engraftment, spread, extension of projections, differentiation towards neurons and glia and functional connectivity with the endogenous ENS.
• This is the first report of in vivo transplantation of human gutderived ENCC and provides proof-of-concept data for their clinical application in cell replacement therapies.
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(n = 5) and 75 ± 14% (n = 5), respectively. Transduced cells maintained fluorescence and formed GFP/GCaMP-expressing neurospheres after 7-10 days in vitro (inset in Fig. 1A ).
Human fetal GFP+ or GCaMP+ labeled cells were transplanted, as neurospheres, into the distal gut of Rag2 were neuronal (Fig. 1G ). 3D reconstruction of confocal images revealed the fine structure of the physical connections of the transplanted human-derived GCaMP+ neurons and the endogenous ENS (Fig. 1H) .
| DISCUSSION
A number of studies using murine cells support the idea of using stem cell transplantation for the treatment of enteric neuropathies such as Hirschsprung disease. [12] [13] [14] As a first step to explore the potential of human gut-derived ENCC for in vivo transplantation, we sought to study fetal enteric neural stem cells. We have previously shown that neurospheres containing such cells are formed faster and with higher efficiency than their postnatal counterparts. 16 We wished to confirm that committed human ENCCs sourced early in development retain the potential for cell therapy. To this end, we demonstrated that fetal gut-derived ENCC can be efficiently isolated from the enteric cell population by sorting for p75 (25.6 ± 2.5%), with a greater efficiency than that achieved by ourselves and others for postnatal gut-derived ENCC (5.8 ± 2.8%; D.
Natarajan, unpublished findings and 4.82; SEM = 1.43%, respectively).
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These ENCC can be labeled using lentiviral constructs to facilitate subsequent cell tracing and functional studies. Human fetal ENCC proved successful at colonizing postnatal mouse colon, forming extensive networks of neurons and glia, which physically integrated with the endogenous ENS. Crucially we showed, for the first time, the functional integration of transplanted human gut-derived cells within in vivo gut.
Having confirmed the ability of fetal human gut-derived ENCC to functionally colonize the intact ENS, a number of challenges remain to be addressed. These include determining whether these cells retain functionality and elicit rescue within a model of enteric neuropathic disease, if they are safe to transplant and indeed whether they are a viable cell source for use in a therapeutic setting.
Previously, we reported higher cell engraftment outcomes following in vivo transplantation of mouse-derived ENCC (90.3%) in contrast to 53.3% in this study. This is likely to reflect both our experience Disease in vivo. 23 Although the transplanted cells appeared to show efficient pan-colonic colonization and were able to rescue the lethal phenotype of this model, the authors were unable to comment on the mechanism by which rescue may have been elicited and functionality of the transplanted cells was not demonstrated. 23 Although their work is a step toward validation of the use of ESC in enteric neuropathies, ESC safety for transplantation, in terms of colonizing off-target locations and tumorigenicity, was not addressed. In our study, we successfully harvested a cell type already committed to the ENS lineage, theoretically reducing the risk of uncontrolled proliferation. This is supported by our previous work using mouse-derived ENCC, which provided evidence that this cell type is safe to transplant within an in vivo environment. 13 Such safety data must be further extended to human gut-derived ENCC.
Here, we used fetal human gut-derived ENCC as a cell source with which to demonstrate the ability of human ENCC to integrate functionally with the ENS in vivo. Given concerns regarding the sourcing and use of fetal (and embryonic) cells as a therapeutic tool, our current studies aim to investigate the capabilities of postnatally sourced ENCC within the in vivo environment. We and others have demonstrated that ENCC can be sourced from routine mucosal gut biopsies of both children and adults. 14, 24, 25 Clinically, these cells could benefit from being autologously sourced from minimally invasive procedures, thus circumventing both ethical concerns and any requirement for immunosuppression upon transplantation. However, several challenges remain to be addressed including optimization of protocols to maximize the proliferative capacity of postnatal-derived cells, and convincing demonstration of their functional viability.
In conclusion, our findings advance the search for a cell replace- 
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